Bright Machines offers free automation service to develop medical devices
Category: #health  By Pankaj Singh  Date: 2020-03-20
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

Bright Machines offers free automation service to develop medical devices

As the world comes together to fight against the deadly COVID-19 virus, more and more organizations are pledging their support to find a treatment for this novel disease. Recently, Bright Machines, a smart manufacturing firm, made a similar move when it announced its latest initiative to eradicate the issue of medical product shortages amidst the COVID-19 pandemic.

Reportedly, Bright Machines is planning to offer one-year, no-cost automation for manufacturing devices that are essential for devising a treatment for coronavirus. After evaluating all the recent drug development measures, it has now become clear that both an adequate supply of treatment resources, particularly respirators & ventilators, and access to testing is crucial for effective drug development.

To help simplify the issue of making essential medical devices readily available, Bright Machines would offer no-cost access for nearly 12 months on any of its Microfactory deployment that is linked with the COVID-19 response.

These Microfactories would help drug developers to quickly scale up their production by employing modular automation that is less dependent on human operators as to traditional inspection and assembly processes.

Evidently, Bright Machines Select is the firm’s microfactory-as-a-service model, that offers all the advantages of Software-Defined Manufacturing to drug developers without the downside of enduring traditional automation equipment’s associated upfront costs.

For the record, Bright Machines possesses deep experience in the automation space, and had recently joined hands with Diagnostics for the Real World (DRW) to automate the manufacturing of DRW’s pioneering SAMBA testing and diagnostic platform.

Elaborating about the benefits of Bright Machines Select, the model simplifies the process of budgeting, contracts, and financial evaluation for manufacturers. Moreover, the platform eliminates friction and optimizes the purchasing process for drug developers that are eyeing to deploy smart automation to enhance their lines.

Speaking on Bright Machine Select, Amar Hanspal, CEO, Bright Machines, said that the company has the vision to democratize the way products get manufactured so that people can attain products made using cost-effective & efficient production techniques at remote locations.

Source Credit: https://finance.yahoo.com/news/bright-machines-moves-scale-medical-150000000.html



About Author

Pankaj Singh

Email: [email protected]   linkdin twitter

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

More News By Pankaj Singh

LVMH revamps La Samaritaine store and opens it in tourist-less Paris

LVMH revamps La Samaritaine store and opens it in tourist-less Paris

By Pankaj Singh

La Samaritaine, a historic landmark of 19th century France, has been reportedly revamped as a new destination for dining, all-in-one shopping, and tourism by LVMH, a French luxury conglomerate. The stores&rs...

Nanjing Bioheng Biotech obtains ODD from US FDA for treating T-ALL

Nanjing Bioheng Biotech obtains ODD from US FDA for treating T-ALL

By Pankaj Singh

Bioheng Biotech Co. Ltd. has reportedly announced that its CD7-targeting T-cell therapy product, code CTD401, has obtained the Orphan Drug Designation (ODD) from the US FDA for treating T-cell acute lymphoblastic leuke...

Tiziana to initiate development of ‘Take Home’ nasal COVID treatment

Tiziana to initiate development of ‘Take Home’ nasal COVID treatment

By Pankaj Singh

Biotechnology company, Tiziana Life Sciences plc, has reportedly announced the submission of a grant to the UK-CTAP (United Kingdom COVID Therapeutics Advisory Panel).

This ...